Antipsychotic-induced Tardive dyskinesia: from biological basis to clinical management. (2nd September 2017)

• Record Type: Journal Article
• Authors: Salem, Haitham; Pigott, Teresa; Zhang, Xiang Y.; Zeni, Cristian P.; Teixeira, Antonio L.
• Is Part Of: Expert review of neurotherapeutics. Volume 17:Number 9(2017)
• Page Start: 883
• Page End: 894
• Publication Date: 2017-09-02
• Subjects: Tardive dyskinesia -- movement disorders -- antipsychotics -- neuroleptics -- dopamine receptor blockers -- schizophrenia; Neuropharmacology -- Periodicals; 615.7805
• DOI: 10.1080/14737175.2017.1361322
• Languages: English
• ISSNs: 1473-7175

Abstract

ABSTRACT: Introduction : Tardive dyskinesia (TD) is a chronic and disabling movement disorder with a complex pathophysiological basis. A significant percentage of patients does not receive correct diagnosis, resulting in delayed or inaccurate treatment and poor outcome. Therefore, there is a critical need for prompt recognition, implementation of efficacious treatment regimens and long-term follow up of patients with TD. Areas covered : The current paper provides an overview of emerging data concerning proposed pathophysiology theories, epidemiology, risk factors, and therapeutic strategies for TD. Expert commentary : Despite considerable research efforts, TD remains a challenge in the treatment of psychosis as the available strategies remain sub-optimal. The best scenario will always be the prophylaxis or prevention of TD, which entails limiting the use of antipsychotics.